SlideShare a Scribd company logo
1 of 89
Alexandre Naime Barbosa MD, PhD 
Professor Assistente - Infectologista 
Preceptoria de Residência em Infectologia 
FMB - UNESP - Botucatu 
2014
Barbosa AN, 2014
Animação Virtual: http://youtu.be/Y8h2wzwdzZs Hodder Arnold - Use of Antibiotics 
Barbosa AN, 2014
Animação Virtual: http://youtu.be/Y8h2wzwdzZs Manns, M - Nature Reviews - 2013 
Barbosa AN, 2014
Manns, M - Nature Reviews - 2013 
Barbosa AN, 2014
Manns, M - Nature Reviews - 2013 
Barbosa AN, 2014
Barbosa AN, 2014
Slide cedido pelo Dr. Deílson de Elgui 
Barbosa AN, 2014
Barbosa AN, 2014
University of Washington - 2014 
Barbosa AN, 2014
Barbosa AN, 2014
Slide cedido pela Dra. Aline Vigani 
Barbosa AN, 2014
Dçs Cerebrovasculares 
17.08% 
Infarto Miocárdio 
13.66% 
Câncer 
12.42% 
Pneumonias 
9.47% 
Cirrose e Dçs 
Outras Dçs Isq 
Coração 
3.46% 
Sepse 
2.25% 
Dçs Hipertensivas 
7.66% 
Dçs Pulmonares Crônicas 
Diabete Mellitus 
9.39% 
8.88% 
Insuf. Cardíaca 
4.72% 
Fígado 
3.31% 
Miocardiopatia 
2.29% 
Aids 
2.08% 
Insuf. Renal 
1.98% 
Demais Doenças Perinatais 
1.35% 
Barbosa AN, 2014
Barbosa AN, 2014
Mundo Brasil 
Prevalência 170 - 200 milhões 2 - 3 milhões 
Incidência/ano 3 - 4 milhões 10 mil 
Mortalidade/ano 0.3 milhão ? 
Barbosa AN, 2014 
> 10% 
2,5-10% 
1-2,5% 
Prevalência 
ND 
WHO, 2012 
Inquérito Nacional das Hepatites Virais, MS-Brasil, 2010
Barbosa AN, 2014 
VHB 
VHC 
10 – 50 anos
Oliveira U. B., 2010 
Barbosa AN, 2014
Barbosa AN, 2014 
VHB VHC 
Parceiros Sexuais de VHB + Transfusões antes de 1994 
Múltiplos Parceiros, Violência Sexual Usuários de Drogas 
DSTs (HIV, VHC, Lues, HPV, etc) Hemofílicos, Hemodiálise 
HSHs HSHs 
Usuários de Drogas Acidentes Ocupacionais 
Convívio Domiciliar com VHB + Seringas e Agulhas Não Descartáveis 
Acidentes Ocupacionais Acupuntura, Piercing ou Tatuagem 
Hemodiálise Parceiros Sexuais de VHC + 
Institucionalizados Convívio Domiciliar com VHC + 
Viajantes para Áreas Endêmicas DSTs (HIV, VHC, Lues, HPV, etc) 
Filhos de Mães VHB + Filhos de Mães VHC + 
Sinais de Hepatopatia Sinais de Hepatopatia
Slide cedido pelo Dr. Paulo Abraão 
Barbosa AN, 2014
Slide cedido pelo Dr. Paulo Abraão 
Barbosa AN, 2014
Slide cedido pelo Dr. Paulo Abraão 
Barbosa AN, 2014
Slide cedido pelo Dr. Paulo Abraão 
Barbosa AN, 2014
Barbosa AN, 2014
Slide cedido pela Dra. Aline Vigani 
Barbosa AN, 2014
Slide cedido pelo Dr. Paulo Abraão 
Barbosa AN, 2014
Slide cedido pela Dra. Aline Vigani 
Barbosa AN, 2014
Slide cedido pela Dra. Aline Vigani 
Barbosa AN, 2014
Barbosa AN, 2014
Barbosa AN, 2014
Barbosa AN, 2014
Barbosa AN, 2014 
Fluxograma de Tratamento (PEG-IFN + RBV) 
Sem 4 Sem 12 Sem 24 Sem 48 Sem 72 
PCR VHC 
(-) 
PCR VHC (-) Sem 4: 
Resposta Virológica Rápida 
RVS: 90%
Sem 4 Sem 12 Sem 24 Sem 48 Sem 72 
Barbosa AN, 2014 
Fluxograma de Tratamento (PEG-IFN + RBV) 
G2/3 
G1 
Tto: 24 semanas 
Tto: 48 semanas 
PCR VHC 
(-) 
PCR VHC (-) Sem 4: 
Resposta Virológica Rápida 
RVS: 90%
Barbosa AN, 2014 
Fluxograma de Tratamento (PEG-IFN + RBV) 
Sem 4 Sem 12 Sem 24 Sem 48 Sem 72 
PCR VHC (-) Sem 12: 
Resposta Virológica 
Precoce Completa 
PCR VHC RVS: 66% 
(+) 
PCR VHC 
(-)
Barbosa AN, 2014 
Fluxograma de Tratamento (PEG-IFN + RBV) 
Sem 4 Sem 12 Sem 24 Sem 48 Sem 72 
PCR VHC 
(+) 
G2/3 
G1 
Tto: 24 semanas 
Tto: 48 semanas 
PCR VHC 
(-) 
G2/3 
G1 
PCR VHC 
(-) 
PCR VHC (-) Sem 12: 
Resposta Virológica 
Precoce Completa 
RVS: 66%
Barbosa AN, 2014 
Fluxograma de Tratamento (PEG-IFN + RBV) 
Sem 4 Sem 12 Sem 24 Sem 48 Sem 72 
Queda de 
2 logs 
PCR VHC 
(+) 
Queda de 2 logs Sem 12: 
Resposta Virológica 
Precoce Parcial 
RVS: 45%
Barbosa AN, 2014 
Fluxograma de Tratamento (PEG-IFN + RBV) 
Sem 4 Sem 12 Sem 24 Sem 48 Sem 72 
PCR VHC 
(+) 
G2/3 
G1 
Tto: 24 semanas 
Tto: 48 semanas 
PCR VHC 
(-) 
G2/3 
G1 
PCR VHC 
(-) 
Queda de 2 logs Sem 12: 
Resposta Virológica 
Precoce Parcial 
RVS: 45% 
Queda de 
2 logs 
G1 
Tto: 72 semanas 
G2/3
Barbosa AN, 2014 
Fluxograma de Tratamento (PEG-IFN + RBV) 
Sem 4 Sem 12 Sem 24 Sem 48 Sem 72 
PCR VHC 
(+) 
PCR VHC 
(-) 
Queda de 
2 logs 
Sem queda 
De 2 logs 
Sem Queda de 2 logs 
Sem 12: Resposta Nula 
RVS: 2 %
Sem Queda de 2 logs 
Sem 12: Resposta 
Barbosa AN, 2014 
Fluxograma de Tratamento (PEG-IFN + RBV) 
Sem 4 Sem 12 Sem 24 Sem 48 Sem 72 
PCR VHC 
(+) 
G2/3 
G1 
Tto: 24 semanas 
Tto: 48 semanas 
PCR VHC 
(-) 
G2/3 
G1 
PCR VHC 
(-) 
Queda de 
2 logs 
G1 
Tto: 72 semanas 
Sem queda 
De 2 logs 
G1/2/3 
Nula 
Tto: Suspenso 
G2/3
Barbosa AN, 2014 
Fluxograma de Tratamento (PEG-IFN + RBV) 
Sem 4 Sem 12 Sem 24 Sem 48 Sem 72 
PCR VHC 
(+) 
G2/3 
G1 
Tto: 24 semanas 
Tto: 48 semanas 
PCR VHC 
(-) 
G2/3 
G1 
PCR VHC 
(-) 
Queda de 
2 logs 
G2/3 
G1 
Tto: 72 semanas 
Sem queda 
De 2 logs 
G1/2/3 
PCR VHC Tto: Suspenso 
(+)
Barbosa AN, 2014 
Desafios 
- Efeitos Adversos 
- Interações Medicamentosas (HIV) 
- Recidivantes e Não Respondedores (50%) 
- Diagnóstico Tardio, Alcoolismo, Fibrose Avançada
Barbosa AN, 2014
Slide cedido pela Dra. Aline Vigani 
Barbosa AN, 2014
Slide cedido pela Dra. Aline Vigani 
Barbosa AN, 2014
Slide cedido pela Dra. Aline Vigani 
Barbosa AN, 2014
Protease Inhibitor Additional Regimen 
Components 
Considerations 
Boceprevir 800 mg TID (q7- 
9hrs)[1,2] 
PegIFN alfa 
+ 
weight-based RBV 
 Naive to previous therapy 
 Previous treatment failure 
 Compensated cirrhosis 
 RGT 
 Take with food 
Telaprevir 750 mg TID 
(q7-9hrs)[2,3] 
PegIFN alfa 
+ 
weight-based RBV 
 Naive to previous therapy 
 Previous treatment failure 
 Compensated cirrhosis 
 RGT 
 Take with food (not low fat) 
For patients with genotype 2/3 infection, HCV therapy with pegIFN/RBV 
remains the standard of care 
1. Boceprevir [package insert]. 2011. 2. Ghany MG, et al. Hepatology. 2011;54:1433-1444. 
3. Telaprevir [package insert]. 2011. 
Barbosa AN, 2014
 Telaprevir 
– Treatment-naive 
– ADVANCE[1] 
– ILLUMINATE[2] 
– Treatment-experienced 
– REALIZE[3] 
 Boceprevir 
– Treatment-naive 
– SPRINT-2[4] 
– Treatment-experienced 
– RESPOND-2[5] 
1. Jacobson IM, et al. N Engl J Med. 2011;364:2405-2416. 2. Sherman KE, et al. N Engl J Med. 2011;365:1014-1024. 3. Zeuzem S, et al. N Engl J Med. 2011;364:2417-2428. 4. 
Poordad F, et al. N Engl J Med. 2011;364:1195-1206. 5. Bacon BR, et al. N Engl J Med. 2011;364:1207-1217. 
Barbosa AN, 2014
BOC + PegIFN + RBV 
PegIFN + RBV 
PegIFN 
+ RBV 
BOC + PegIFN + RBV 
0 4 8 12 24 
28 36 
48 
Early response*; stop at Wk 28; f/u 
24 wks 
F/u 
24 wks 
Boceprevir[1,2] 
Telaprevir[2,3] 
TVR + PegIFN + RBV 
eRVR†; stop at Wk 24, f/u 24 wks 
PegIFN + RBV F/u 
24 wks 
0 4 12 24 48 
*Undetectable HCV RNA at Wk 8 of therapy (Wk 4 of triple therapy). 
†Undetectable HCV RNA at Wks 4 and 12 of triple therapy. 
1. Boceprevir [package insert]. May 2011. 2. Ghany MG, et al. Hepatology. 2011;54:1433-1444. 
3. Telaprevir [package insert]. May 2011. 
No eRVR †; PegIFN + RBV 
Barbosa AN, 2014
P < .001 
P < .001 
Nonblack Patients 
P = .004 
P = .04 
Black Patients 
125/ 
311 
211/ 
316 
213/ 
311 
12/ 
52 
22/ 
52 
29/ 
55 
Patients 
(%) 
PR 48 BOC RGT 
100 
80 
60 
40 
20 
0 
BOC/PR48 
40 
67 68 
Patients 
(%) 
PR 48 BOC RGT 
100 
80 
60 
40 
20 
0 
BOC/PR48 
23 
42 
53 
n/ 
N= 
n/ 
N= 
Poordad F, et al. N Engl J Med. 2011;364:1195-1206. 
SPRINT-2 
Barbosa AN, 2014
P < .001 
100 
SVR (%) 
80 
60 
40 
20 
0 
75 
271/ 
363 
44 
158/ 
361 
PR T12PR 
n/ 
N = 
100 
80 
60 
40 
20 
1. Jacobson IM, et al. N Engl J Med. 2011;364:2405-2416. 
2. Dusheiko GM, et al. EASL 2011. Abstract 1788. 
Pooled Analysis From ADVANCE 
and ILLUMINATE[2] 
ADVANCE[1] 
SVR (%) 
0 
PR T12PR 
n/ 
N = 
Nonblack 
Black 
75 
599/ 
804 
61 
60/ 
99 
45 
151/ 
333 
25 
7/ 
28 
Barbosa AN, 2014
BOC + PegIFN + RBV 
PegIFN 
+ RBV 
0 4 8 12 24 28 36 
48 
PegIFN 
+ RBV 
BOC + PegIFN + RBV 
Boceprevir [package insert]. May 2011. Ghany MG, et al. Hepatology. 2011;54:1433-1444. 
Early response; stop at Wk 28; 
f/u 24 wks 
HCV RNA 
Undetectable Undetectable 
PegIFN + RBV 
0 4 12 28 48 
8 24 
36 
HCV RNA 
Detectable Undetectable Slow response; extend triple therapy 
to Wk 36; PR to Wk 48; f/u 24 wks 
< 100 IU/mL 
< 100 IU/mL 
Barbosa AN, 2014
SPRINT-2: BOC + PegIFN/RBV in GT1 Treatment-Naive Patients 
HCV RNA undetectable 
at Weeks 8 and 24 
HCV RNA detectable at Week 8, 
undetectable at Week 24 
Nonblacks 
100 
80 
60 
40 
20 
0 
PR48 BOC/PR 
RGT 
Poordad F, et al. N Engl J Med. 2011;364:1195-1206. 
BOC/PR 
48 Wks 
93 
66 
97 
74 
96 
74 
37/ 
40 
78/ 
118 
143/ 
147 
52/ 
70 
137/ 
142 
48/ 
65 
95 88 
Blacks 
SVR (%) 
100 
80 
60 
40 
20 
0 
PR48 BOC/PR 
RGT 
BOC/PR 
48 Wks 
100 
62 
87 
58 
n/ 
N = 
3/ 
3 
8/ 
13 
13/ 
15 
7/ 
12 
18/ 
19 
7/ 
8 
 57% of patients eligible for shorter therapy 
Barbosa AN, 2014
 Recommendation: Noncirrhotic patients can be considered for 
response-guided therapy with TVR 
TVR + PegIFN + RBV 
PegIFN + RBV eRVR; stop at Wk 24, f/u 24 wks 
0 4 12 24 48 
TVR + PegIFN + RBV 
0 4 12 24 48 
Telaprevir [package insert]. May 2011. Ghany MG, et al. Hepatology. 2011;54:1433-1444. 
PegIFN + RBV 
HCV RNA 
Undetectable Undetectable 
Detectable 
(≤ 1000 IU/mL) 
Undetectable or 
detectable (≤ 1000 IU/mL) 
No eRVR; extend pegIFN + RBV to Wk 48; f/u 24 wks 
HCV RNA 
Barbosa AN, 2014
ILLUMINATE: Response-Guided TVR 
+ PegIFN/RBV in 
Treatment-Naive Genotype 1 
 65% of patients eligible for 
shortened therapy[1] 
92 88 
T12PR24 T12PR48 
SVR in Pts Achieving eRVR 
100 
(%) 
80 
60 
40 
20 
0 
149/ 
162 
140/ 
160 
n/ 
N= 
ADVANCE: TVR + PegIFN/RBV in 
Treatment-Naive Genotype 1 
 58% of patients eligible for 
shortened therapy[2] 
89 
100 
1. Jacobson IM, et al. N Engl J Med. 2011;364:2405-2416. 
2. Sherman KE, et al. N Engl J Med. 2011;365:1014-1024. 
97 
T12PR24 T12PR48 
SVR in Pts Achieving eRVR 
(%) 
80 
60 
40 
20 
0 
189/ 
212 
28/ 
29 
n/ 
N= 
Barbosa AN, 2014
BOC[1,2] 
Time Point Criteria Action 
Wk 12 HCV RNA ≥ 100 IU/mL Discontinue all therapy 
Wk 24 HCV RNA detectable Discontinue all therapy 
TVR[1,3] 
Time Point Criteria Action 
Wk 4 or 12 HCV RNA > 1000 IU/mL Discontinue all therapy 
Wk 24 HCV RNA detectable Discontinue pegIFN/RBV 
Assay should have a lower limit of HCV RNA quantification of ≤ 25 IU/mL and a limit of HCV RNA 
detection of approximately 10-15 IU/mL. 
1. Boceprevir [package insert]. May 2011. 2. Ghany MG, et al. Hepatology. 2011;54:1433-1444. 
3. Telaprevir [package insert]. May 2011. 
Barbosa AN, 2014
 Recommendation: BOC approved for previous relapsers, partial, and null responders[1] 
– AASLD guidelines say BOC “recommended” for previous relapsers and partial responders; 
advise caution in null responders given lack of definitive information from phase III studies[2] 
BOC + PegIFN + RBV 
Previous relapse 
100 
80 
60 
40 
20 
0 
PegIFN + RBV 
n/N = 2/29 15/51 23/57 72/105 30/58 77/103 
PegIFN 
+ RBV 
1. Boceprevir [package insert]. 2011. 2. Ghany MG, et al. Hepatology. 2011;54:1433-1444. 
3. Bacon BR, et al. N Engl J Med. 2011;364:1207-1217. 
40 
69 
BOC RGT 
52 
75 
BOC/PR48 
7 
29 
PR48 
SVR (%)[3] 
Previous partial response 
F/u 
24 wks 
BOC + PegIFN + RBV 
0 4 8 12 24 
28 36 
48 
Early response; 
stop at Wk 36; f/u 24 wks 
Barbosa AN, 2014
 Recommendation: Response-guided therapy can be considered for 
previous relapsers, may be considered for previous partial 
responders, but not for previous null responders 
BOC + PegIFN + RBV 
PegIFN 
+ RBV 
0 4 8 12 24 28 36 
48 
PegIFN 
+ RBV 
BOC + PegIFN + RBV 
Boceprevir [package insert]. May 2011. Ghany MG, et al. Hepatology. 2011;54:1433-1444. 
Early response; stop at 
Wk 36; f/u 24 wks 
HCV RNA 
Undetectable Undetectable 
PegIFN + RBV 
0 4 8 12 24 
28 36 
48 
HCV RNA 
Detectable Undetectable Slow response; PR to 
Wk 48; f/u 24 wks 
< 100 IU/mL 
< 100 IU/mL 
Barbosa AN, 2014
 Recommendation: TVR approved for previous relapsers, partial, and null responders[1] 
– AASLD guidelines say TVR “recommended” for previous relapsers and partial responders; 
“may be considered” for previous null responders[2] 
Previous relapsers*[1,2] (same as naives) 
TVR + PegIFN + RBV 
eRVR; stop at Wk 24, f/u 24 wks 
PegIFN + RBV F/u 
24 wks 
0 4 12 24 48 
Previous partial responders† and null responders[1,2] 
1. Telaprevir [package insert]. 2011. 2. Ghany MG, et al. Hepatology. 2011;54:1433-1444. 
F/u 
24 wks 
TVR + PegIFN + RBV 
No eRVR; PegIFN + RBV 
PegIFN + RBV 
0 4 12 24 48 
*Response-guided therapy not studied in relapsers in registration trials. 
†AASLD guidelines say RGT “may be considered” for prior partial responders[2] but package insert 
recommends 48 weeks of therapy[1] 
Barbosa AN, 2014
REALIZE: TVR + PegIFN/RBV in G1 Previous Relapsers and Partial/Null Responders 
Lead-in examined but found not to influence response and not included in TVR label 
100 
60 
20 
0 
SVR (%) 
80 
40 
PR48 T12/PR48 LI T12/PR48 
Previous Relapsers Previous Partial 
Responders 
n/N= 
Previous Null 
Responders 
24 
*P < .001 vs PR48. 
83* 
88* 
121/145 124/141 
16/68 
59* 
54* 
29/49 26/48 
15 
4/27 
29* 
33* 
21/72 25/75 
5 
2/37 
Zeuzem S, et al. N Engl J Med. 2011;364:2417-2428. 
Barbosa AN, 2014
 Recommendation: Response-guided therapy recommended for previous 
relapsers, but not for previous partial or null responders*[1] 
HCV RNA 
Undetectable Undetectable 
TVR + PegIFN + RBV 
PegIFN + RBV eRVR; stop at Wk 24, f/u 24 wks 
0 4 12 24 48 
HCV RNA 
Detectable 
(≤ 1000 IU/mL) 
Undetectable/detectable 
(≤ 1000 IU/mL) 
TVR + PegIFN + RBV 
No eRVR; extend pegIFN + RBV to Week 48; f/u 24 wks 
PegIFN + RBV 
0 4 12 24 48 
*AASLD guidelines say RGT “may be considered” for previous partial responders[2] but package insert 
recommends 48 wks of therapy.[1] 
1. Telaprevir [package insert]. May 2011. 2. Ghany MG, et al. Hepatology. 2011;54:1433-1444. 
Barbosa AN, 2014
 Recommendation: All therapy should be discontinued in 
patients with the following: 
BOC[1,2] 
Time Point Criteria Action 
Wk 12 HCV RNA ≥ 100 IU/mL Discontinue all therapy 
Wk 24 HCV RNA detectable Discontinue all therapy 
TVR[1,3] 
Time Point Criteria Action 
Wk 4 or 12 HCV RNA > 1000 IU/mL Discontinue all therapy 
Wk 24 HCV RNA detectable Discontinue pegIFN/RBV 
Assay should have a lower limit of HCV RNA quantification of ≤ 25 IU/mL and a limit of HCV RNA 
detection of approximately 10-15 IU/mL. 
1. Boceprevir [package insert]. May 2011. 2. Ghany MG, et al. Hepatology. 2011;54:1433-1444. 
3. Telaprevir [package insert]. May 2011. 
Barbosa AN, 2014
Barbosa AN, 2014
Barbosa AN, 2014
 Recommendation: All cirrhotic patients receiving BOC + PR should 
receive 48 weeks of therapy[1,2] 
Subgroup Analysis of SPRINT-2[3] 
PR48 
BOC RGT 
BOC/PR48 
41 
14/ 
34 
F3/4 
100 
80 
60 
40 
20 
0 
SVR (%) 
38 
67 
213/ 
319 
F0/1/2 
n/ 
N= 
38 
9/ 
24 
52 
22/ 
42 
67 
211/ 
313 
1. Boceprevir [package insert]. May 2011. 2. Ghany MG, et al. Hepatology. 2011;54:1433-1444. 
3. Poordad F, et al. NEJM. 2011;364:1195-1206. 4. Bacon BR, et al. NEJM. 2011;364:1207-1217. 
Subgroup Analysis of RESPOND-2[4] 
F3/4 
100 
80 
60 
40 
20 
0 
SVR (%) 
23 
66 
77/ 
117 
F0/1/2 
13 
2/ 
15 
68 
21/ 
31 
44 
14/ 
32 
68 
81/ 
119 
123/ 
328 
n/ 
N= 
14/ 
61 
Barbosa AN, 2014
 Recommendation: All cirrhotic patients receiving TVR + PR may 
PR48 
T12PR 
T8PR 
benefit from 48 weeks of therapy[1,2] 
78 
100 
80 
60 
40 
20 
1. Telaprevir [package insert]. May 2011. 2. Ghany MG, et al. Hepatology. 2011;54:1433-1444. 
3. Jacobson IM, et al. AASLD 2010. Abstract 211. 4. Jacobson IM, et al. NEJM. 2011;364:2405-2416. 
62 
73 
53 
47 
33 
0 
No, Minimal, or Portal Fibrosis Bridging Fibrosis or Cirrhosis 
SVR (%)[3,4] 
134/ 
288 
n/ 
N = 
226/ 
290 
205/ 
279 
24/ 
73 
45/ 
73 
45/ 
85 
Barbosa AN, 2014
 Recommendation: IL28B genotype testing may be considered prior to 
therapy if more information about probability of response or treatment 
duration desired 
IL28B Genotype Predicts Likelihood of SVR With Triple Therapy 
SPRINT-2: BOC + PR48[1] 
SVR (%) 
80 
44/ 
55 
71 
82/ 
115 
59 
26/ 
44 
CC CT TT 
100 
80 
60 
40 
20 
0 
n/ 
N = 
1. Poordad F, et al. EASL 2011. Abstract 12. 2. Jacobson IM, et al. EASL 2011. Abstract 1369. 
ADVANCE: T12PR48*[2] 
SVR (%) 
90 
45/ 
50 
48/ 
68 
16/ 
22 
CC CT TT 
100 
80 
60 
40 
20 
0 
71 73 
n/ 
N = 
*IL28B testing in ADVANCE was in whites only. 
Barbosa AN, 2014
 Recommendation: IL28B genotype testing may be considered prior to 
therapy if more information about probability of response or treatment 
duration desired 
IL28B Genotype Predicts Likelihood of Short-Duration Therapy 
SPRINT-2: BOC + PR[1] 
Eligibility for RGT (%) 
89 
118/ 
132 
52 
158/ 
304 
CC CT/TT 
100 
80 
60 
40 
20 
0 
1. Poordad F, et al. EASL 2011. Abstract 12. 2. Jacobson IM, et al. EASL 2011. Abstract 1369. 
ADVANCE: T12PR*[2] 
Eligibility for RGT (%) 
39/ 
50 
39/ 
68 
10/ 
22 
78 
100 
80 
60 
40 
20 
0 
57 
45 
n/ 
N = 
*IL28B testing in ADVANCE was in whites only. 
CC CT TT 
n/ 
N = 
Barbosa AN, 2014
 Data from T12PR arm only 
71 
152/ 
213 
79 
118/ 
149 
100 
50 
0 
1b 1a 
Genotype 
78 
74 
< 800,000 ≥ 800,000 
HCV RNA (IU/mL) 
62 
78 
F0-2 F3-F4 
Fibrosis 
SVR (%) 
75 
25 
207/ 
281 
64/ 
82 
45/ 
73 
226/ 
290 
n/ 
N = 
Marcellin P, et al. EASL 2011. Abstract 451. 
Barbosa AN, 2014
93/ 
133 
89/ 
134 
100 
50 
0 
118/ 
187 
106/ 
179 
1b 1a 
Genotype 
70 
66 
85 
76 
≤ 800,000 > 800,000 
HCV RNA (IU/mL) 
67 67 
BOC/PR48 
F0-2 F3-F4 
Fibrosis 
SVR (%) 
75 
25 
41/ 
54 
45/ 
53 
213/ 
319 
211/ 
313 
n/ 
N = 
BOC/PR RGT 
63 
59 
63 61 
41 
52 
Poordad F, et al. N Engl J Med. 2011;364:1195-1206. Reddy KR, et al. EASL 2011. Abstract 466. 
14/ 
34 
22/ 
42 
192/ 
314 
197/ 
313 
Barbosa AN, 2014
 Significantly higher rates of anemia, neutropenia, and 
dysgeusia in BOC arms vs control 
Adverse Event, % PR48 
(n = 467) 
BOC + PR RGT/48 
(n = 1225) 
Anemia* 30 50 
Neutropenia 19 25 
Dysgeusia 16 35 
*Anemia was managed with RBV reduction and/or epoetin alfa 
(43% of BOC + PR and 24% of PR). 
Barbosa AN, 2014
 Higher rates of rash, anemia, and anorectal signs/symptoms in TVR 
arms vs control 
Adverse Event, % PR48 
(n = 493) 
TVR + PR RGT/48* 
(n = 1797) 
Rash 34 56 
Anemia† 17 36 
Anorectal events 7 29 
*Pooled results from TVR arms. 
†Anemia was managed with RBV dose modification; epoetin alfa was not permitted. 
 In most subjects, rash was mild to moderate 
– Severe rash in 4%; discontinuation due to rash in 6% of subjects 
– Occurred early, usually first 4 wks, but can occur at any time during TVR 
exposure 
– < 1% had SJS or DRESS (11 cases DRESS and 3 cases SJS) 
Telaprevir [package insert]. May 2011. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/ 
Drugs/AntiviralDrugsAdvisoryCommittee/UCM252562.pdf 
Barbosa AN, 2014
 Recommendation: Anemia should be managed initially 
by reducing the RBV dose[1] 
 Dose reduction of RBV is acceptable 
 Dose reduction of DAA is not acceptable 
 Do not discontinue pegIFN/RBV and continue DAA 
 DAA should not be stopped and then restarted 
 Monitor closely if Hb falls < 10 g/dL 
 ESA agents are unlabeled for HCV anemia and should 
not be used if Hb > 12 g/dL 
1. Ghany MG, et al. Hepatology. 2011;54:1433-1444. 
Barbosa AN, 2014
 Rash management 
– Mild to moderate rash can be treated with oral 
antihistamines, topical steroids 
– Systemic steroids are not recommended 
– Stop all 3 drugs for severe rash, DRESS, or SJS 
– Important to have “go-to” dermatologist; vigilance with rash 
is key 
 Anorectal symptom management 
– Fiber, loperamide, hydrocortisone, and pramoxine topical 
cream 
Telaprevir [package insert]. May 2011. 
Barbosa AN, 2014
 Contraindications for BOC and TVR therapy 
– Patients with previous SAEs leading to premature pegIFN/RBV discontinuation 
– Pregnant women or men whose female partners are pregnant 
– Coadministration with other drugs highly dependent on CYP3A4/5 for clearance 
– Coadministration with potent CYP3A4/5 inducers that may significantly reduce 
BOC or TVR plasma concentrations, leading to reduced efficacy 
 Safety and pharmacokinetics have not been studied in patients with 
decompensated cirrhosis or in liver transplant recipients, patients coinfected 
with HBV or HIV, or persons younger than 18 yrs of age 
 Assess carefully for all drug-drug interactions prior to commencing therapy 
Boceprevir [package insert]. May 2011. Telaprevir [package insert]. May 2011. 
Ghany MG, et al. Hepatology. 2011;54:1433-1444. 
Barbosa AN, 2014
Barbosa AN, 2012
Antirretroviral Boceprevir Telaprevir 
Tenofovir Dose Habitual Dose Habitual (↑ C min TDF, toxicidade?) 
Zidovudina Dose Habitual (↑ risco anemia) Dose Habitual (↑ risco anemia) 
Abacavir Dose Habitual Não recomendado (sem estudos) 
3TC, ddI Dose Habitual Dose Habitual 
Atazanavir Não recomendado Dose Habitual 
DRV, FPV, LOP/r Não recomendado Não recomendado 
Efavirenz Não recomendado Dose: 1125mg 8/8h (↓ C min Telaprevir) 
Nevirapina Não recomendado (sem estudos) Não recomendado (sem estudos) 
Etravirina Dose Habitual (↓ C min ETV; Impacto?) Dose Habitual 
Raltegravir Dose Habitual Dose Habitual 
Maraviroque Dose Habitual (MVQ 150 mg 12/12h) Dose Habitual (MVQ 150 mg 12/12h) 
hep-druginteractions.org 
Barbosa AN, 2014
Slide cedido pela Dra. Aline Vigani 
Barbosa AN, 2014
Barbosa AN, 2014
Slide cedido pela Dra. Aline Vigani 
Barbosa AN, 2014
Slide cedido pela Dra. Aline Vigani 
Barbosa AN, 2014
Slide cedido pela Dra. Aline Vigani 
Barbosa AN, 2014
Slide cedido pela Dra. Aline Vigani 
Barbosa AN, 2014
Slide cedido pela Dra. Aline Vigani 
Barbosa AN, 2014
Barbosa AN, 2014
Slide cedido pela Dra. Aline Vigani 
Barbosa AN, 2014
Slide cedido pela Dra. Aline Vigani 
Barbosa AN, 2014
Slide cedido pela Dra. Aline Vigani 
Barbosa AN, 2014
Slide cedido pela Dra. Aline Vigani 
Barbosa AN, 2014
Slide cedido pela Dra. Aline Vigani 
Barbosa AN, 2014
www.slideshare.net/spitalex

More Related Content

Similar to Hepatite C - Tratamento Atual e Futuro 2014 (Versão Final)

Managing cirrhotic HCV patients. Whom to treat, how to treat.2014
Managing cirrhotic HCV patients. Whom to treat, how to treat.2014Managing cirrhotic HCV patients. Whom to treat, how to treat.2014
Managing cirrhotic HCV patients. Whom to treat, how to treat.2014hivlifeinfo
 
Managing cirrhotic HCV patients. Whom to treat, how to treat.2014
Managing cirrhotic HCV patients. Whom to treat, how to treat.2014Managing cirrhotic HCV patients. Whom to treat, how to treat.2014
Managing cirrhotic HCV patients. Whom to treat, how to treat.2014Hivlife Info
 
Marcellin tt vhb du 2012
Marcellin tt vhb du 2012Marcellin tt vhb du 2012
Marcellin tt vhb du 2012odeckmyn
 
The Role of New HCV Agents in Managing HIV/HCV Coinfection.2014
The Role of New HCV Agents in Managing HIV/HCV Coinfection.2014The Role of New HCV Agents in Managing HIV/HCV Coinfection.2014
The Role of New HCV Agents in Managing HIV/HCV Coinfection.2014hivlifeinfo
 
The Role of New HCV Agents in Managing HIV/HCV Coinfection.2014
The Role of New HCV Agents in Managing HIV/HCV Coinfection.2014The Role of New HCV Agents in Managing HIV/HCV Coinfection.2014
The Role of New HCV Agents in Managing HIV/HCV Coinfection.2014Hivlife Info
 
Benhamou du hv hiv hcv du16
Benhamou du hv hiv hcv du16Benhamou du hv hiv hcv du16
Benhamou du hv hiv hcv du16odeckmyn
 
CẬP NHẬT ĐIỀU TRỊ VIÊM GAN VIRUS C MẠN NĂM 2017
CẬP NHẬT ĐIỀU TRỊ VIÊM GAN VIRUS C MẠN NĂM 2017 CẬP NHẬT ĐIỀU TRỊ VIÊM GAN VIRUS C MẠN NĂM 2017
CẬP NHẬT ĐIỀU TRỊ VIÊM GAN VIRUS C MẠN NĂM 2017 bientap2
 
CẬP NHẬT ĐIỀU TRỊ VIÊM GAN VIRUT MAN NĂM 2017
CẬP NHẬT ĐIỀU TRỊ VIÊM GAN VIRUT MAN NĂM 2017CẬP NHẬT ĐIỀU TRỊ VIÊM GAN VIRUT MAN NĂM 2017
CẬP NHẬT ĐIỀU TRỊ VIÊM GAN VIRUT MAN NĂM 2017Great Doctor
 
Palestra Novos Conceitos na Terapia com Inibidores de Protease - Dr. Jordan Feld
Palestra Novos Conceitos na Terapia com Inibidores de Protease - Dr. Jordan FeldPalestra Novos Conceitos na Terapia com Inibidores de Protease - Dr. Jordan Feld
Palestra Novos Conceitos na Terapia com Inibidores de Protease - Dr. Jordan FeldFabiane Martins
 
Samuel hcv lt du hepatite 1-15
Samuel  hcv  lt du hepatite 1-15Samuel  hcv  lt du hepatite 1-15
Samuel hcv lt du hepatite 1-15odeckmyn
 
Samuel Virus Lt Du Hepatites 09
Samuel Virus Lt Du Hepatites 09Samuel Virus Lt Du Hepatites 09
Samuel Virus Lt Du Hepatites 09odeckmyn
 
Challenges in HCV Management
Challenges in HCV Management Challenges in HCV Management
Challenges in HCV Management drnkhokhar
 
ESSENCE OF SOFOSBUVIR 400mg.
ESSENCE OF SOFOSBUVIR 400mg.ESSENCE OF SOFOSBUVIR 400mg.
ESSENCE OF SOFOSBUVIR 400mg.Tajammul Siddiq
 
20141015-Resistance & seroreversion of HBV
20141015-Resistance & seroreversion of HBV20141015-Resistance & seroreversion of HBV
20141015-Resistance & seroreversion of HBV建豪 陳
 
HCV Alerts- Rapid Response to Practice-Changing Advances From EASL 2015
HCV Alerts- Rapid Response to Practice-Changing Advances From EASL 2015HCV Alerts- Rapid Response to Practice-Changing Advances From EASL 2015
HCV Alerts- Rapid Response to Practice-Changing Advances From EASL 2015Hivlife Info
 
HCV Alerts- Rapid Response to Practice-Changing Advances From EASL 2015
HCV Alerts- Rapid Response to Practice-Changing Advances From EASL 2015HCV Alerts- Rapid Response to Practice-Changing Advances From EASL 2015
HCV Alerts- Rapid Response to Practice-Changing Advances From EASL 2015hivlifeinfo
 

Similar to Hepatite C - Tratamento Atual e Futuro 2014 (Versão Final) (20)

Cadth 2015 a3 ramji
Cadth 2015 a3 ramjiCadth 2015 a3 ramji
Cadth 2015 a3 ramji
 
Managing cirrhotic HCV patients. Whom to treat, how to treat.2014
Managing cirrhotic HCV patients. Whom to treat, how to treat.2014Managing cirrhotic HCV patients. Whom to treat, how to treat.2014
Managing cirrhotic HCV patients. Whom to treat, how to treat.2014
 
Managing cirrhotic HCV patients. Whom to treat, how to treat.2014
Managing cirrhotic HCV patients. Whom to treat, how to treat.2014Managing cirrhotic HCV patients. Whom to treat, how to treat.2014
Managing cirrhotic HCV patients. Whom to treat, how to treat.2014
 
Marcellin tt vhb du 2012
Marcellin tt vhb du 2012Marcellin tt vhb du 2012
Marcellin tt vhb du 2012
 
The Role of New HCV Agents in Managing HIV/HCV Coinfection.2014
The Role of New HCV Agents in Managing HIV/HCV Coinfection.2014The Role of New HCV Agents in Managing HIV/HCV Coinfection.2014
The Role of New HCV Agents in Managing HIV/HCV Coinfection.2014
 
The Role of New HCV Agents in Managing HIV/HCV Coinfection.2014
The Role of New HCV Agents in Managing HIV/HCV Coinfection.2014The Role of New HCV Agents in Managing HIV/HCV Coinfection.2014
The Role of New HCV Agents in Managing HIV/HCV Coinfection.2014
 
Nova Era no Tratamento do Vírus da Hepatite C
Nova Era no Tratamento do Vírus da Hepatite CNova Era no Tratamento do Vírus da Hepatite C
Nova Era no Tratamento do Vírus da Hepatite C
 
ppt
pptppt
ppt
 
Benhamou du hv hiv hcv du16
Benhamou du hv hiv hcv du16Benhamou du hv hiv hcv du16
Benhamou du hv hiv hcv du16
 
HCV Story ---by Mohammed Hussien
HCV Story ---by Mohammed HussienHCV Story ---by Mohammed Hussien
HCV Story ---by Mohammed Hussien
 
CẬP NHẬT ĐIỀU TRỊ VIÊM GAN VIRUS C MẠN NĂM 2017
CẬP NHẬT ĐIỀU TRỊ VIÊM GAN VIRUS C MẠN NĂM 2017 CẬP NHẬT ĐIỀU TRỊ VIÊM GAN VIRUS C MẠN NĂM 2017
CẬP NHẬT ĐIỀU TRỊ VIÊM GAN VIRUS C MẠN NĂM 2017
 
CẬP NHẬT ĐIỀU TRỊ VIÊM GAN VIRUT MAN NĂM 2017
CẬP NHẬT ĐIỀU TRỊ VIÊM GAN VIRUT MAN NĂM 2017CẬP NHẬT ĐIỀU TRỊ VIÊM GAN VIRUT MAN NĂM 2017
CẬP NHẬT ĐIỀU TRỊ VIÊM GAN VIRUT MAN NĂM 2017
 
Palestra Novos Conceitos na Terapia com Inibidores de Protease - Dr. Jordan Feld
Palestra Novos Conceitos na Terapia com Inibidores de Protease - Dr. Jordan FeldPalestra Novos Conceitos na Terapia com Inibidores de Protease - Dr. Jordan Feld
Palestra Novos Conceitos na Terapia com Inibidores de Protease - Dr. Jordan Feld
 
Samuel hcv lt du hepatite 1-15
Samuel  hcv  lt du hepatite 1-15Samuel  hcv  lt du hepatite 1-15
Samuel hcv lt du hepatite 1-15
 
Samuel Virus Lt Du Hepatites 09
Samuel Virus Lt Du Hepatites 09Samuel Virus Lt Du Hepatites 09
Samuel Virus Lt Du Hepatites 09
 
Challenges in HCV Management
Challenges in HCV Management Challenges in HCV Management
Challenges in HCV Management
 
ESSENCE OF SOFOSBUVIR 400mg.
ESSENCE OF SOFOSBUVIR 400mg.ESSENCE OF SOFOSBUVIR 400mg.
ESSENCE OF SOFOSBUVIR 400mg.
 
20141015-Resistance & seroreversion of HBV
20141015-Resistance & seroreversion of HBV20141015-Resistance & seroreversion of HBV
20141015-Resistance & seroreversion of HBV
 
HCV Alerts- Rapid Response to Practice-Changing Advances From EASL 2015
HCV Alerts- Rapid Response to Practice-Changing Advances From EASL 2015HCV Alerts- Rapid Response to Practice-Changing Advances From EASL 2015
HCV Alerts- Rapid Response to Practice-Changing Advances From EASL 2015
 
HCV Alerts- Rapid Response to Practice-Changing Advances From EASL 2015
HCV Alerts- Rapid Response to Practice-Changing Advances From EASL 2015HCV Alerts- Rapid Response to Practice-Changing Advances From EASL 2015
HCV Alerts- Rapid Response to Practice-Changing Advances From EASL 2015
 

More from Alexandre Naime Barbosa

Novas Estratégias de PrEP e PEP PrEP Sob Demanda, Longa Duração e DoxiPEP
Novas Estratégias de PrEP e PEP  PrEP Sob Demanda, Longa Duração e DoxiPEPNovas Estratégias de PrEP e PEP  PrEP Sob Demanda, Longa Duração e DoxiPEP
Novas Estratégias de PrEP e PEP PrEP Sob Demanda, Longa Duração e DoxiPEPAlexandre Naime Barbosa
 
Covid-19 Leve Atualizacao do Manejo Clinico
Covid-19 Leve Atualizacao do Manejo ClinicoCovid-19 Leve Atualizacao do Manejo Clinico
Covid-19 Leve Atualizacao do Manejo ClinicoAlexandre Naime Barbosa
 
Efetividade Vacinas Covid CNNEI 2022.pptx
Efetividade Vacinas Covid CNNEI 2022.pptxEfetividade Vacinas Covid CNNEI 2022.pptx
Efetividade Vacinas Covid CNNEI 2022.pptxAlexandre Naime Barbosa
 
Dengue - Epidemiologia e Manejo InfectoNNE Out 2022 v2.pptx
Dengue - Epidemiologia e Manejo InfectoNNE Out 2022 v2.pptxDengue - Epidemiologia e Manejo InfectoNNE Out 2022 v2.pptx
Dengue - Epidemiologia e Manejo InfectoNNE Out 2022 v2.pptxAlexandre Naime Barbosa
 
Doencas Emergentes Pos Pandemia CFM 2022
Doencas Emergentes Pos Pandemia CFM 2022Doencas Emergentes Pos Pandemia CFM 2022
Doencas Emergentes Pos Pandemia CFM 2022Alexandre Naime Barbosa
 
Desafios Divulgação Cientifica Pandemia.pptx
Desafios Divulgação Cientifica Pandemia.pptxDesafios Divulgação Cientifica Pandemia.pptx
Desafios Divulgação Cientifica Pandemia.pptxAlexandre Naime Barbosa
 
SARS-COV-2 e Covid-19 Atualização do Manejo Clínico
SARS-COV-2 e Covid-19 Atualização do Manejo ClínicoSARS-COV-2 e Covid-19 Atualização do Manejo Clínico
SARS-COV-2 e Covid-19 Atualização do Manejo ClínicoAlexandre Naime Barbosa
 
Diretriz Tratamento Covid SBI InfectoSul.pptx
Diretriz Tratamento Covid SBI InfectoSul.pptxDiretriz Tratamento Covid SBI InfectoSul.pptx
Diretriz Tratamento Covid SBI InfectoSul.pptxAlexandre Naime Barbosa
 
Hepatite C - Situação atual do tratamento no contexto do Brasil
Hepatite C - Situação atual do tratamento no contexto do BrasilHepatite C - Situação atual do tratamento no contexto do Brasil
Hepatite C - Situação atual do tratamento no contexto do BrasilAlexandre Naime Barbosa
 
Covid-19 Moderada/Grave Tratamento de Pacientes Hospitalizados
Covid-19 Moderada/Grave Tratamento de Pacientes HospitalizadosCovid-19 Moderada/Grave Tratamento de Pacientes Hospitalizados
Covid-19 Moderada/Grave Tratamento de Pacientes HospitalizadosAlexandre Naime Barbosa
 
Dengue - Impacto Epidemiologico e Manejo Clinico
Dengue - Impacto Epidemiologico e Manejo ClinicoDengue - Impacto Epidemiologico e Manejo Clinico
Dengue - Impacto Epidemiologico e Manejo ClinicoAlexandre Naime Barbosa
 
Prevencao e Terapeutica da Covid-19 com Anticorpos Monoclonais
Prevencao e Terapeutica da Covid-19 com Anticorpos MonoclonaisPrevencao e Terapeutica da Covid-19 com Anticorpos Monoclonais
Prevencao e Terapeutica da Covid-19 com Anticorpos MonoclonaisAlexandre Naime Barbosa
 
Atualizacoes Aprendizados e Perspectivas Pandemia Covid
Atualizacoes Aprendizados e Perspectivas Pandemia CovidAtualizacoes Aprendizados e Perspectivas Pandemia Covid
Atualizacoes Aprendizados e Perspectivas Pandemia CovidAlexandre Naime Barbosa
 

More from Alexandre Naime Barbosa (20)

Novas Estratégias de PrEP e PEP PrEP Sob Demanda, Longa Duração e DoxiPEP
Novas Estratégias de PrEP e PEP  PrEP Sob Demanda, Longa Duração e DoxiPEPNovas Estratégias de PrEP e PEP  PrEP Sob Demanda, Longa Duração e DoxiPEP
Novas Estratégias de PrEP e PEP PrEP Sob Demanda, Longa Duração e DoxiPEP
 
Vacuna anti COVID-19 2023
Vacuna anti COVID-19 2023Vacuna anti COVID-19 2023
Vacuna anti COVID-19 2023
 
Covid-19 Leve Atualizacao do Manejo Clinico
Covid-19 Leve Atualizacao do Manejo ClinicoCovid-19 Leve Atualizacao do Manejo Clinico
Covid-19 Leve Atualizacao do Manejo Clinico
 
Monkeypox CMBT Nov 2022.pptx
Monkeypox CMBT Nov 2022.pptxMonkeypox CMBT Nov 2022.pptx
Monkeypox CMBT Nov 2022.pptx
 
Efetividade Vacinas Covid CNNEI 2022.pptx
Efetividade Vacinas Covid CNNEI 2022.pptxEfetividade Vacinas Covid CNNEI 2022.pptx
Efetividade Vacinas Covid CNNEI 2022.pptx
 
Dengue - Epidemiologia e Manejo InfectoNNE Out 2022 v2.pptx
Dengue - Epidemiologia e Manejo InfectoNNE Out 2022 v2.pptxDengue - Epidemiologia e Manejo InfectoNNE Out 2022 v2.pptx
Dengue - Epidemiologia e Manejo InfectoNNE Out 2022 v2.pptx
 
Doencas Emergentes Pos Pandemia CFM 2022
Doencas Emergentes Pos Pandemia CFM 2022Doencas Emergentes Pos Pandemia CFM 2022
Doencas Emergentes Pos Pandemia CFM 2022
 
Desafios Divulgação Cientifica Pandemia.pptx
Desafios Divulgação Cientifica Pandemia.pptxDesafios Divulgação Cientifica Pandemia.pptx
Desafios Divulgação Cientifica Pandemia.pptx
 
SARS-COV-2 e Covid-19 Atualização do Manejo Clínico
SARS-COV-2 e Covid-19 Atualização do Manejo ClínicoSARS-COV-2 e Covid-19 Atualização do Manejo Clínico
SARS-COV-2 e Covid-19 Atualização do Manejo Clínico
 
Movimentos Anti-Vacina Brasil 2022.pptx
Movimentos Anti-Vacina Brasil 2022.pptxMovimentos Anti-Vacina Brasil 2022.pptx
Movimentos Anti-Vacina Brasil 2022.pptx
 
Diretriz Tratamento Covid SBI InfectoSul.pptx
Diretriz Tratamento Covid SBI InfectoSul.pptxDiretriz Tratamento Covid SBI InfectoSul.pptx
Diretriz Tratamento Covid SBI InfectoSul.pptx
 
Hepatite C - Situação atual do tratamento no contexto do Brasil
Hepatite C - Situação atual do tratamento no contexto do BrasilHepatite C - Situação atual do tratamento no contexto do Brasil
Hepatite C - Situação atual do tratamento no contexto do Brasil
 
Covid-19 Moderada/Grave Tratamento de Pacientes Hospitalizados
Covid-19 Moderada/Grave Tratamento de Pacientes HospitalizadosCovid-19 Moderada/Grave Tratamento de Pacientes Hospitalizados
Covid-19 Moderada/Grave Tratamento de Pacientes Hospitalizados
 
Uso Racional Antibioticos Idosos
Uso Racional Antibioticos IdososUso Racional Antibioticos Idosos
Uso Racional Antibioticos Idosos
 
Infeccao pelo HIV e Covid-19
Infeccao pelo HIV e Covid-19Infeccao pelo HIV e Covid-19
Infeccao pelo HIV e Covid-19
 
Dengue - Impacto Epidemiologico e Manejo Clinico
Dengue - Impacto Epidemiologico e Manejo ClinicoDengue - Impacto Epidemiologico e Manejo Clinico
Dengue - Impacto Epidemiologico e Manejo Clinico
 
Hepatite C - O que falta resolver?
Hepatite C - O que falta resolver?Hepatite C - O que falta resolver?
Hepatite C - O que falta resolver?
 
Novas Perspectivas no Manejo Covid 2022
Novas Perspectivas no Manejo Covid 2022Novas Perspectivas no Manejo Covid 2022
Novas Perspectivas no Manejo Covid 2022
 
Prevencao e Terapeutica da Covid-19 com Anticorpos Monoclonais
Prevencao e Terapeutica da Covid-19 com Anticorpos MonoclonaisPrevencao e Terapeutica da Covid-19 com Anticorpos Monoclonais
Prevencao e Terapeutica da Covid-19 com Anticorpos Monoclonais
 
Atualizacoes Aprendizados e Perspectivas Pandemia Covid
Atualizacoes Aprendizados e Perspectivas Pandemia CovidAtualizacoes Aprendizados e Perspectivas Pandemia Covid
Atualizacoes Aprendizados e Perspectivas Pandemia Covid
 

Recently uploaded

blood bank management system project report
blood bank management system project reportblood bank management system project report
blood bank management system project reportNARMADAPETROLEUMGAS
 
historyofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusanguhistoryofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusangu Medical University
 
Adenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisAdenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisSujoy Dasgupta
 
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.aarjukhadka22
 
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxDNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxMAsifAhmad
 
Mental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil ThirusanguMental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil Thirusangu Medical University
 
Female Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyFemale Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyMedicoseAcademics
 
Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Peter Embi
 
How to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyHow to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyZurück zum Ursprung
 
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfSGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfHongBiThi1
 
BENIGN BREAST DISEASE
BENIGN BREAST DISEASE BENIGN BREAST DISEASE
BENIGN BREAST DISEASE Mamatha Lakka
 
Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.kishan singh tomar
 
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptxORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptxNIKITA BHUTE
 
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfSGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfHongBiThi1
 
Neurological history taking (2024) .
Neurological  history  taking  (2024)  .Neurological  history  taking  (2024)  .
Neurological history taking (2024) .Mohamed Rizk Khodair
 
Using Data Visualization in Public Health Communications
Using Data Visualization in Public Health CommunicationsUsing Data Visualization in Public Health Communications
Using Data Visualization in Public Health Communicationskatiequigley33
 
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfCONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfDolisha Warbi
 

Recently uploaded (20)

American College of physicians ACP high value care recommendations in rheumat...
American College of physicians ACP high value care recommendations in rheumat...American College of physicians ACP high value care recommendations in rheumat...
American College of physicians ACP high value care recommendations in rheumat...
 
blood bank management system project report
blood bank management system project reportblood bank management system project report
blood bank management system project report
 
historyofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusanguhistoryofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusangu
 
Adenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisAdenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosis
 
How to master Steroid (glucocorticoids) prescription, different scenarios, ca...
How to master Steroid (glucocorticoids) prescription, different scenarios, ca...How to master Steroid (glucocorticoids) prescription, different scenarios, ca...
How to master Steroid (glucocorticoids) prescription, different scenarios, ca...
 
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
 
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxDNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
 
Mental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil ThirusanguMental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil Thirusangu
 
Female Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyFemale Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before Pregnancy
 
Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024
 
Rheumatoid arthritis Part 1, case based approach with application of the late...
Rheumatoid arthritis Part 1, case based approach with application of the late...Rheumatoid arthritis Part 1, case based approach with application of the late...
Rheumatoid arthritis Part 1, case based approach with application of the late...
 
How to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyHow to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturally
 
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfSGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
 
BENIGN BREAST DISEASE
BENIGN BREAST DISEASE BENIGN BREAST DISEASE
BENIGN BREAST DISEASE
 
Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.
 
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptxORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptx
 
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfSGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
 
Neurological history taking (2024) .
Neurological  history  taking  (2024)  .Neurological  history  taking  (2024)  .
Neurological history taking (2024) .
 
Using Data Visualization in Public Health Communications
Using Data Visualization in Public Health CommunicationsUsing Data Visualization in Public Health Communications
Using Data Visualization in Public Health Communications
 
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfCONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
 

Hepatite C - Tratamento Atual e Futuro 2014 (Versão Final)

  • 1. Alexandre Naime Barbosa MD, PhD Professor Assistente - Infectologista Preceptoria de Residência em Infectologia FMB - UNESP - Botucatu 2014
  • 3. Animação Virtual: http://youtu.be/Y8h2wzwdzZs Hodder Arnold - Use of Antibiotics Barbosa AN, 2014
  • 4. Animação Virtual: http://youtu.be/Y8h2wzwdzZs Manns, M - Nature Reviews - 2013 Barbosa AN, 2014
  • 5. Manns, M - Nature Reviews - 2013 Barbosa AN, 2014
  • 6. Manns, M - Nature Reviews - 2013 Barbosa AN, 2014
  • 8. Slide cedido pelo Dr. Deílson de Elgui Barbosa AN, 2014
  • 10. University of Washington - 2014 Barbosa AN, 2014
  • 12. Slide cedido pela Dra. Aline Vigani Barbosa AN, 2014
  • 13. Dçs Cerebrovasculares 17.08% Infarto Miocárdio 13.66% Câncer 12.42% Pneumonias 9.47% Cirrose e Dçs Outras Dçs Isq Coração 3.46% Sepse 2.25% Dçs Hipertensivas 7.66% Dçs Pulmonares Crônicas Diabete Mellitus 9.39% 8.88% Insuf. Cardíaca 4.72% Fígado 3.31% Miocardiopatia 2.29% Aids 2.08% Insuf. Renal 1.98% Demais Doenças Perinatais 1.35% Barbosa AN, 2014
  • 15. Mundo Brasil Prevalência 170 - 200 milhões 2 - 3 milhões Incidência/ano 3 - 4 milhões 10 mil Mortalidade/ano 0.3 milhão ? Barbosa AN, 2014 > 10% 2,5-10% 1-2,5% Prevalência ND WHO, 2012 Inquérito Nacional das Hepatites Virais, MS-Brasil, 2010
  • 16. Barbosa AN, 2014 VHB VHC 10 – 50 anos
  • 17. Oliveira U. B., 2010 Barbosa AN, 2014
  • 18. Barbosa AN, 2014 VHB VHC Parceiros Sexuais de VHB + Transfusões antes de 1994 Múltiplos Parceiros, Violência Sexual Usuários de Drogas DSTs (HIV, VHC, Lues, HPV, etc) Hemofílicos, Hemodiálise HSHs HSHs Usuários de Drogas Acidentes Ocupacionais Convívio Domiciliar com VHB + Seringas e Agulhas Não Descartáveis Acidentes Ocupacionais Acupuntura, Piercing ou Tatuagem Hemodiálise Parceiros Sexuais de VHC + Institucionalizados Convívio Domiciliar com VHC + Viajantes para Áreas Endêmicas DSTs (HIV, VHC, Lues, HPV, etc) Filhos de Mães VHB + Filhos de Mães VHC + Sinais de Hepatopatia Sinais de Hepatopatia
  • 19. Slide cedido pelo Dr. Paulo Abraão Barbosa AN, 2014
  • 20. Slide cedido pelo Dr. Paulo Abraão Barbosa AN, 2014
  • 21. Slide cedido pelo Dr. Paulo Abraão Barbosa AN, 2014
  • 22. Slide cedido pelo Dr. Paulo Abraão Barbosa AN, 2014
  • 24. Slide cedido pela Dra. Aline Vigani Barbosa AN, 2014
  • 25. Slide cedido pelo Dr. Paulo Abraão Barbosa AN, 2014
  • 26. Slide cedido pela Dra. Aline Vigani Barbosa AN, 2014
  • 27. Slide cedido pela Dra. Aline Vigani Barbosa AN, 2014
  • 31. Barbosa AN, 2014 Fluxograma de Tratamento (PEG-IFN + RBV) Sem 4 Sem 12 Sem 24 Sem 48 Sem 72 PCR VHC (-) PCR VHC (-) Sem 4: Resposta Virológica Rápida RVS: 90%
  • 32. Sem 4 Sem 12 Sem 24 Sem 48 Sem 72 Barbosa AN, 2014 Fluxograma de Tratamento (PEG-IFN + RBV) G2/3 G1 Tto: 24 semanas Tto: 48 semanas PCR VHC (-) PCR VHC (-) Sem 4: Resposta Virológica Rápida RVS: 90%
  • 33. Barbosa AN, 2014 Fluxograma de Tratamento (PEG-IFN + RBV) Sem 4 Sem 12 Sem 24 Sem 48 Sem 72 PCR VHC (-) Sem 12: Resposta Virológica Precoce Completa PCR VHC RVS: 66% (+) PCR VHC (-)
  • 34. Barbosa AN, 2014 Fluxograma de Tratamento (PEG-IFN + RBV) Sem 4 Sem 12 Sem 24 Sem 48 Sem 72 PCR VHC (+) G2/3 G1 Tto: 24 semanas Tto: 48 semanas PCR VHC (-) G2/3 G1 PCR VHC (-) PCR VHC (-) Sem 12: Resposta Virológica Precoce Completa RVS: 66%
  • 35. Barbosa AN, 2014 Fluxograma de Tratamento (PEG-IFN + RBV) Sem 4 Sem 12 Sem 24 Sem 48 Sem 72 Queda de 2 logs PCR VHC (+) Queda de 2 logs Sem 12: Resposta Virológica Precoce Parcial RVS: 45%
  • 36. Barbosa AN, 2014 Fluxograma de Tratamento (PEG-IFN + RBV) Sem 4 Sem 12 Sem 24 Sem 48 Sem 72 PCR VHC (+) G2/3 G1 Tto: 24 semanas Tto: 48 semanas PCR VHC (-) G2/3 G1 PCR VHC (-) Queda de 2 logs Sem 12: Resposta Virológica Precoce Parcial RVS: 45% Queda de 2 logs G1 Tto: 72 semanas G2/3
  • 37. Barbosa AN, 2014 Fluxograma de Tratamento (PEG-IFN + RBV) Sem 4 Sem 12 Sem 24 Sem 48 Sem 72 PCR VHC (+) PCR VHC (-) Queda de 2 logs Sem queda De 2 logs Sem Queda de 2 logs Sem 12: Resposta Nula RVS: 2 %
  • 38. Sem Queda de 2 logs Sem 12: Resposta Barbosa AN, 2014 Fluxograma de Tratamento (PEG-IFN + RBV) Sem 4 Sem 12 Sem 24 Sem 48 Sem 72 PCR VHC (+) G2/3 G1 Tto: 24 semanas Tto: 48 semanas PCR VHC (-) G2/3 G1 PCR VHC (-) Queda de 2 logs G1 Tto: 72 semanas Sem queda De 2 logs G1/2/3 Nula Tto: Suspenso G2/3
  • 39. Barbosa AN, 2014 Fluxograma de Tratamento (PEG-IFN + RBV) Sem 4 Sem 12 Sem 24 Sem 48 Sem 72 PCR VHC (+) G2/3 G1 Tto: 24 semanas Tto: 48 semanas PCR VHC (-) G2/3 G1 PCR VHC (-) Queda de 2 logs G2/3 G1 Tto: 72 semanas Sem queda De 2 logs G1/2/3 PCR VHC Tto: Suspenso (+)
  • 40. Barbosa AN, 2014 Desafios - Efeitos Adversos - Interações Medicamentosas (HIV) - Recidivantes e Não Respondedores (50%) - Diagnóstico Tardio, Alcoolismo, Fibrose Avançada
  • 42. Slide cedido pela Dra. Aline Vigani Barbosa AN, 2014
  • 43. Slide cedido pela Dra. Aline Vigani Barbosa AN, 2014
  • 44. Slide cedido pela Dra. Aline Vigani Barbosa AN, 2014
  • 45. Protease Inhibitor Additional Regimen Components Considerations Boceprevir 800 mg TID (q7- 9hrs)[1,2] PegIFN alfa + weight-based RBV  Naive to previous therapy  Previous treatment failure  Compensated cirrhosis  RGT  Take with food Telaprevir 750 mg TID (q7-9hrs)[2,3] PegIFN alfa + weight-based RBV  Naive to previous therapy  Previous treatment failure  Compensated cirrhosis  RGT  Take with food (not low fat) For patients with genotype 2/3 infection, HCV therapy with pegIFN/RBV remains the standard of care 1. Boceprevir [package insert]. 2011. 2. Ghany MG, et al. Hepatology. 2011;54:1433-1444. 3. Telaprevir [package insert]. 2011. Barbosa AN, 2014
  • 46.  Telaprevir – Treatment-naive – ADVANCE[1] – ILLUMINATE[2] – Treatment-experienced – REALIZE[3]  Boceprevir – Treatment-naive – SPRINT-2[4] – Treatment-experienced – RESPOND-2[5] 1. Jacobson IM, et al. N Engl J Med. 2011;364:2405-2416. 2. Sherman KE, et al. N Engl J Med. 2011;365:1014-1024. 3. Zeuzem S, et al. N Engl J Med. 2011;364:2417-2428. 4. Poordad F, et al. N Engl J Med. 2011;364:1195-1206. 5. Bacon BR, et al. N Engl J Med. 2011;364:1207-1217. Barbosa AN, 2014
  • 47. BOC + PegIFN + RBV PegIFN + RBV PegIFN + RBV BOC + PegIFN + RBV 0 4 8 12 24 28 36 48 Early response*; stop at Wk 28; f/u 24 wks F/u 24 wks Boceprevir[1,2] Telaprevir[2,3] TVR + PegIFN + RBV eRVR†; stop at Wk 24, f/u 24 wks PegIFN + RBV F/u 24 wks 0 4 12 24 48 *Undetectable HCV RNA at Wk 8 of therapy (Wk 4 of triple therapy). †Undetectable HCV RNA at Wks 4 and 12 of triple therapy. 1. Boceprevir [package insert]. May 2011. 2. Ghany MG, et al. Hepatology. 2011;54:1433-1444. 3. Telaprevir [package insert]. May 2011. No eRVR †; PegIFN + RBV Barbosa AN, 2014
  • 48. P < .001 P < .001 Nonblack Patients P = .004 P = .04 Black Patients 125/ 311 211/ 316 213/ 311 12/ 52 22/ 52 29/ 55 Patients (%) PR 48 BOC RGT 100 80 60 40 20 0 BOC/PR48 40 67 68 Patients (%) PR 48 BOC RGT 100 80 60 40 20 0 BOC/PR48 23 42 53 n/ N= n/ N= Poordad F, et al. N Engl J Med. 2011;364:1195-1206. SPRINT-2 Barbosa AN, 2014
  • 49. P < .001 100 SVR (%) 80 60 40 20 0 75 271/ 363 44 158/ 361 PR T12PR n/ N = 100 80 60 40 20 1. Jacobson IM, et al. N Engl J Med. 2011;364:2405-2416. 2. Dusheiko GM, et al. EASL 2011. Abstract 1788. Pooled Analysis From ADVANCE and ILLUMINATE[2] ADVANCE[1] SVR (%) 0 PR T12PR n/ N = Nonblack Black 75 599/ 804 61 60/ 99 45 151/ 333 25 7/ 28 Barbosa AN, 2014
  • 50. BOC + PegIFN + RBV PegIFN + RBV 0 4 8 12 24 28 36 48 PegIFN + RBV BOC + PegIFN + RBV Boceprevir [package insert]. May 2011. Ghany MG, et al. Hepatology. 2011;54:1433-1444. Early response; stop at Wk 28; f/u 24 wks HCV RNA Undetectable Undetectable PegIFN + RBV 0 4 12 28 48 8 24 36 HCV RNA Detectable Undetectable Slow response; extend triple therapy to Wk 36; PR to Wk 48; f/u 24 wks < 100 IU/mL < 100 IU/mL Barbosa AN, 2014
  • 51. SPRINT-2: BOC + PegIFN/RBV in GT1 Treatment-Naive Patients HCV RNA undetectable at Weeks 8 and 24 HCV RNA detectable at Week 8, undetectable at Week 24 Nonblacks 100 80 60 40 20 0 PR48 BOC/PR RGT Poordad F, et al. N Engl J Med. 2011;364:1195-1206. BOC/PR 48 Wks 93 66 97 74 96 74 37/ 40 78/ 118 143/ 147 52/ 70 137/ 142 48/ 65 95 88 Blacks SVR (%) 100 80 60 40 20 0 PR48 BOC/PR RGT BOC/PR 48 Wks 100 62 87 58 n/ N = 3/ 3 8/ 13 13/ 15 7/ 12 18/ 19 7/ 8  57% of patients eligible for shorter therapy Barbosa AN, 2014
  • 52.  Recommendation: Noncirrhotic patients can be considered for response-guided therapy with TVR TVR + PegIFN + RBV PegIFN + RBV eRVR; stop at Wk 24, f/u 24 wks 0 4 12 24 48 TVR + PegIFN + RBV 0 4 12 24 48 Telaprevir [package insert]. May 2011. Ghany MG, et al. Hepatology. 2011;54:1433-1444. PegIFN + RBV HCV RNA Undetectable Undetectable Detectable (≤ 1000 IU/mL) Undetectable or detectable (≤ 1000 IU/mL) No eRVR; extend pegIFN + RBV to Wk 48; f/u 24 wks HCV RNA Barbosa AN, 2014
  • 53. ILLUMINATE: Response-Guided TVR + PegIFN/RBV in Treatment-Naive Genotype 1  65% of patients eligible for shortened therapy[1] 92 88 T12PR24 T12PR48 SVR in Pts Achieving eRVR 100 (%) 80 60 40 20 0 149/ 162 140/ 160 n/ N= ADVANCE: TVR + PegIFN/RBV in Treatment-Naive Genotype 1  58% of patients eligible for shortened therapy[2] 89 100 1. Jacobson IM, et al. N Engl J Med. 2011;364:2405-2416. 2. Sherman KE, et al. N Engl J Med. 2011;365:1014-1024. 97 T12PR24 T12PR48 SVR in Pts Achieving eRVR (%) 80 60 40 20 0 189/ 212 28/ 29 n/ N= Barbosa AN, 2014
  • 54. BOC[1,2] Time Point Criteria Action Wk 12 HCV RNA ≥ 100 IU/mL Discontinue all therapy Wk 24 HCV RNA detectable Discontinue all therapy TVR[1,3] Time Point Criteria Action Wk 4 or 12 HCV RNA > 1000 IU/mL Discontinue all therapy Wk 24 HCV RNA detectable Discontinue pegIFN/RBV Assay should have a lower limit of HCV RNA quantification of ≤ 25 IU/mL and a limit of HCV RNA detection of approximately 10-15 IU/mL. 1. Boceprevir [package insert]. May 2011. 2. Ghany MG, et al. Hepatology. 2011;54:1433-1444. 3. Telaprevir [package insert]. May 2011. Barbosa AN, 2014
  • 55.  Recommendation: BOC approved for previous relapsers, partial, and null responders[1] – AASLD guidelines say BOC “recommended” for previous relapsers and partial responders; advise caution in null responders given lack of definitive information from phase III studies[2] BOC + PegIFN + RBV Previous relapse 100 80 60 40 20 0 PegIFN + RBV n/N = 2/29 15/51 23/57 72/105 30/58 77/103 PegIFN + RBV 1. Boceprevir [package insert]. 2011. 2. Ghany MG, et al. Hepatology. 2011;54:1433-1444. 3. Bacon BR, et al. N Engl J Med. 2011;364:1207-1217. 40 69 BOC RGT 52 75 BOC/PR48 7 29 PR48 SVR (%)[3] Previous partial response F/u 24 wks BOC + PegIFN + RBV 0 4 8 12 24 28 36 48 Early response; stop at Wk 36; f/u 24 wks Barbosa AN, 2014
  • 56.  Recommendation: Response-guided therapy can be considered for previous relapsers, may be considered for previous partial responders, but not for previous null responders BOC + PegIFN + RBV PegIFN + RBV 0 4 8 12 24 28 36 48 PegIFN + RBV BOC + PegIFN + RBV Boceprevir [package insert]. May 2011. Ghany MG, et al. Hepatology. 2011;54:1433-1444. Early response; stop at Wk 36; f/u 24 wks HCV RNA Undetectable Undetectable PegIFN + RBV 0 4 8 12 24 28 36 48 HCV RNA Detectable Undetectable Slow response; PR to Wk 48; f/u 24 wks < 100 IU/mL < 100 IU/mL Barbosa AN, 2014
  • 57.  Recommendation: TVR approved for previous relapsers, partial, and null responders[1] – AASLD guidelines say TVR “recommended” for previous relapsers and partial responders; “may be considered” for previous null responders[2] Previous relapsers*[1,2] (same as naives) TVR + PegIFN + RBV eRVR; stop at Wk 24, f/u 24 wks PegIFN + RBV F/u 24 wks 0 4 12 24 48 Previous partial responders† and null responders[1,2] 1. Telaprevir [package insert]. 2011. 2. Ghany MG, et al. Hepatology. 2011;54:1433-1444. F/u 24 wks TVR + PegIFN + RBV No eRVR; PegIFN + RBV PegIFN + RBV 0 4 12 24 48 *Response-guided therapy not studied in relapsers in registration trials. †AASLD guidelines say RGT “may be considered” for prior partial responders[2] but package insert recommends 48 weeks of therapy[1] Barbosa AN, 2014
  • 58. REALIZE: TVR + PegIFN/RBV in G1 Previous Relapsers and Partial/Null Responders Lead-in examined but found not to influence response and not included in TVR label 100 60 20 0 SVR (%) 80 40 PR48 T12/PR48 LI T12/PR48 Previous Relapsers Previous Partial Responders n/N= Previous Null Responders 24 *P < .001 vs PR48. 83* 88* 121/145 124/141 16/68 59* 54* 29/49 26/48 15 4/27 29* 33* 21/72 25/75 5 2/37 Zeuzem S, et al. N Engl J Med. 2011;364:2417-2428. Barbosa AN, 2014
  • 59.  Recommendation: Response-guided therapy recommended for previous relapsers, but not for previous partial or null responders*[1] HCV RNA Undetectable Undetectable TVR + PegIFN + RBV PegIFN + RBV eRVR; stop at Wk 24, f/u 24 wks 0 4 12 24 48 HCV RNA Detectable (≤ 1000 IU/mL) Undetectable/detectable (≤ 1000 IU/mL) TVR + PegIFN + RBV No eRVR; extend pegIFN + RBV to Week 48; f/u 24 wks PegIFN + RBV 0 4 12 24 48 *AASLD guidelines say RGT “may be considered” for previous partial responders[2] but package insert recommends 48 wks of therapy.[1] 1. Telaprevir [package insert]. May 2011. 2. Ghany MG, et al. Hepatology. 2011;54:1433-1444. Barbosa AN, 2014
  • 60.  Recommendation: All therapy should be discontinued in patients with the following: BOC[1,2] Time Point Criteria Action Wk 12 HCV RNA ≥ 100 IU/mL Discontinue all therapy Wk 24 HCV RNA detectable Discontinue all therapy TVR[1,3] Time Point Criteria Action Wk 4 or 12 HCV RNA > 1000 IU/mL Discontinue all therapy Wk 24 HCV RNA detectable Discontinue pegIFN/RBV Assay should have a lower limit of HCV RNA quantification of ≤ 25 IU/mL and a limit of HCV RNA detection of approximately 10-15 IU/mL. 1. Boceprevir [package insert]. May 2011. 2. Ghany MG, et al. Hepatology. 2011;54:1433-1444. 3. Telaprevir [package insert]. May 2011. Barbosa AN, 2014
  • 63.  Recommendation: All cirrhotic patients receiving BOC + PR should receive 48 weeks of therapy[1,2] Subgroup Analysis of SPRINT-2[3] PR48 BOC RGT BOC/PR48 41 14/ 34 F3/4 100 80 60 40 20 0 SVR (%) 38 67 213/ 319 F0/1/2 n/ N= 38 9/ 24 52 22/ 42 67 211/ 313 1. Boceprevir [package insert]. May 2011. 2. Ghany MG, et al. Hepatology. 2011;54:1433-1444. 3. Poordad F, et al. NEJM. 2011;364:1195-1206. 4. Bacon BR, et al. NEJM. 2011;364:1207-1217. Subgroup Analysis of RESPOND-2[4] F3/4 100 80 60 40 20 0 SVR (%) 23 66 77/ 117 F0/1/2 13 2/ 15 68 21/ 31 44 14/ 32 68 81/ 119 123/ 328 n/ N= 14/ 61 Barbosa AN, 2014
  • 64.  Recommendation: All cirrhotic patients receiving TVR + PR may PR48 T12PR T8PR benefit from 48 weeks of therapy[1,2] 78 100 80 60 40 20 1. Telaprevir [package insert]. May 2011. 2. Ghany MG, et al. Hepatology. 2011;54:1433-1444. 3. Jacobson IM, et al. AASLD 2010. Abstract 211. 4. Jacobson IM, et al. NEJM. 2011;364:2405-2416. 62 73 53 47 33 0 No, Minimal, or Portal Fibrosis Bridging Fibrosis or Cirrhosis SVR (%)[3,4] 134/ 288 n/ N = 226/ 290 205/ 279 24/ 73 45/ 73 45/ 85 Barbosa AN, 2014
  • 65.  Recommendation: IL28B genotype testing may be considered prior to therapy if more information about probability of response or treatment duration desired IL28B Genotype Predicts Likelihood of SVR With Triple Therapy SPRINT-2: BOC + PR48[1] SVR (%) 80 44/ 55 71 82/ 115 59 26/ 44 CC CT TT 100 80 60 40 20 0 n/ N = 1. Poordad F, et al. EASL 2011. Abstract 12. 2. Jacobson IM, et al. EASL 2011. Abstract 1369. ADVANCE: T12PR48*[2] SVR (%) 90 45/ 50 48/ 68 16/ 22 CC CT TT 100 80 60 40 20 0 71 73 n/ N = *IL28B testing in ADVANCE was in whites only. Barbosa AN, 2014
  • 66.  Recommendation: IL28B genotype testing may be considered prior to therapy if more information about probability of response or treatment duration desired IL28B Genotype Predicts Likelihood of Short-Duration Therapy SPRINT-2: BOC + PR[1] Eligibility for RGT (%) 89 118/ 132 52 158/ 304 CC CT/TT 100 80 60 40 20 0 1. Poordad F, et al. EASL 2011. Abstract 12. 2. Jacobson IM, et al. EASL 2011. Abstract 1369. ADVANCE: T12PR*[2] Eligibility for RGT (%) 39/ 50 39/ 68 10/ 22 78 100 80 60 40 20 0 57 45 n/ N = *IL28B testing in ADVANCE was in whites only. CC CT TT n/ N = Barbosa AN, 2014
  • 67.  Data from T12PR arm only 71 152/ 213 79 118/ 149 100 50 0 1b 1a Genotype 78 74 < 800,000 ≥ 800,000 HCV RNA (IU/mL) 62 78 F0-2 F3-F4 Fibrosis SVR (%) 75 25 207/ 281 64/ 82 45/ 73 226/ 290 n/ N = Marcellin P, et al. EASL 2011. Abstract 451. Barbosa AN, 2014
  • 68. 93/ 133 89/ 134 100 50 0 118/ 187 106/ 179 1b 1a Genotype 70 66 85 76 ≤ 800,000 > 800,000 HCV RNA (IU/mL) 67 67 BOC/PR48 F0-2 F3-F4 Fibrosis SVR (%) 75 25 41/ 54 45/ 53 213/ 319 211/ 313 n/ N = BOC/PR RGT 63 59 63 61 41 52 Poordad F, et al. N Engl J Med. 2011;364:1195-1206. Reddy KR, et al. EASL 2011. Abstract 466. 14/ 34 22/ 42 192/ 314 197/ 313 Barbosa AN, 2014
  • 69.  Significantly higher rates of anemia, neutropenia, and dysgeusia in BOC arms vs control Adverse Event, % PR48 (n = 467) BOC + PR RGT/48 (n = 1225) Anemia* 30 50 Neutropenia 19 25 Dysgeusia 16 35 *Anemia was managed with RBV reduction and/or epoetin alfa (43% of BOC + PR and 24% of PR). Barbosa AN, 2014
  • 70.  Higher rates of rash, anemia, and anorectal signs/symptoms in TVR arms vs control Adverse Event, % PR48 (n = 493) TVR + PR RGT/48* (n = 1797) Rash 34 56 Anemia† 17 36 Anorectal events 7 29 *Pooled results from TVR arms. †Anemia was managed with RBV dose modification; epoetin alfa was not permitted.  In most subjects, rash was mild to moderate – Severe rash in 4%; discontinuation due to rash in 6% of subjects – Occurred early, usually first 4 wks, but can occur at any time during TVR exposure – < 1% had SJS or DRESS (11 cases DRESS and 3 cases SJS) Telaprevir [package insert]. May 2011. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/ Drugs/AntiviralDrugsAdvisoryCommittee/UCM252562.pdf Barbosa AN, 2014
  • 71.  Recommendation: Anemia should be managed initially by reducing the RBV dose[1]  Dose reduction of RBV is acceptable  Dose reduction of DAA is not acceptable  Do not discontinue pegIFN/RBV and continue DAA  DAA should not be stopped and then restarted  Monitor closely if Hb falls < 10 g/dL  ESA agents are unlabeled for HCV anemia and should not be used if Hb > 12 g/dL 1. Ghany MG, et al. Hepatology. 2011;54:1433-1444. Barbosa AN, 2014
  • 72.  Rash management – Mild to moderate rash can be treated with oral antihistamines, topical steroids – Systemic steroids are not recommended – Stop all 3 drugs for severe rash, DRESS, or SJS – Important to have “go-to” dermatologist; vigilance with rash is key  Anorectal symptom management – Fiber, loperamide, hydrocortisone, and pramoxine topical cream Telaprevir [package insert]. May 2011. Barbosa AN, 2014
  • 73.  Contraindications for BOC and TVR therapy – Patients with previous SAEs leading to premature pegIFN/RBV discontinuation – Pregnant women or men whose female partners are pregnant – Coadministration with other drugs highly dependent on CYP3A4/5 for clearance – Coadministration with potent CYP3A4/5 inducers that may significantly reduce BOC or TVR plasma concentrations, leading to reduced efficacy  Safety and pharmacokinetics have not been studied in patients with decompensated cirrhosis or in liver transplant recipients, patients coinfected with HBV or HIV, or persons younger than 18 yrs of age  Assess carefully for all drug-drug interactions prior to commencing therapy Boceprevir [package insert]. May 2011. Telaprevir [package insert]. May 2011. Ghany MG, et al. Hepatology. 2011;54:1433-1444. Barbosa AN, 2014
  • 75. Antirretroviral Boceprevir Telaprevir Tenofovir Dose Habitual Dose Habitual (↑ C min TDF, toxicidade?) Zidovudina Dose Habitual (↑ risco anemia) Dose Habitual (↑ risco anemia) Abacavir Dose Habitual Não recomendado (sem estudos) 3TC, ddI Dose Habitual Dose Habitual Atazanavir Não recomendado Dose Habitual DRV, FPV, LOP/r Não recomendado Não recomendado Efavirenz Não recomendado Dose: 1125mg 8/8h (↓ C min Telaprevir) Nevirapina Não recomendado (sem estudos) Não recomendado (sem estudos) Etravirina Dose Habitual (↓ C min ETV; Impacto?) Dose Habitual Raltegravir Dose Habitual Dose Habitual Maraviroque Dose Habitual (MVQ 150 mg 12/12h) Dose Habitual (MVQ 150 mg 12/12h) hep-druginteractions.org Barbosa AN, 2014
  • 76. Slide cedido pela Dra. Aline Vigani Barbosa AN, 2014
  • 78. Slide cedido pela Dra. Aline Vigani Barbosa AN, 2014
  • 79. Slide cedido pela Dra. Aline Vigani Barbosa AN, 2014
  • 80. Slide cedido pela Dra. Aline Vigani Barbosa AN, 2014
  • 81. Slide cedido pela Dra. Aline Vigani Barbosa AN, 2014
  • 82. Slide cedido pela Dra. Aline Vigani Barbosa AN, 2014
  • 84. Slide cedido pela Dra. Aline Vigani Barbosa AN, 2014
  • 85. Slide cedido pela Dra. Aline Vigani Barbosa AN, 2014
  • 86. Slide cedido pela Dra. Aline Vigani Barbosa AN, 2014
  • 87. Slide cedido pela Dra. Aline Vigani Barbosa AN, 2014
  • 88. Slide cedido pela Dra. Aline Vigani Barbosa AN, 2014